Download PDF
Thromb Haemost 2002; 87(02): 346-347
DOI: 10.1055/s-0037-1613000
Letters to the Editor
Schattauer GmbH

Successful Use of Recombinant Activated Factor VII (Novoseven®) in Controlling Severe Intra-Abdominal Bleeding after Liver Needle Biopsy

R. Hoffman
1   Department of Hematology, Rambam Medical Center and Brace Rappaport Faculty of Medicine, Technion, Haifa, Israel
,
A. Mahajana
2   Department of Surgery A, Rambam Medical Center and Brace Rappaport Faculty of Medicine, Technion, Haifa, Israel
,
P. Agmon
3   Department of Internal Medicine A, Rambam Medical Center and Brace Rappaport Faculty of Medicine, Technion, Haifa, Israel
,
Y. Barach
4   Department of Hepatology, Rambam Medical Center and Brace Rappaport Faculty of Medicine, Technion, Haifa, Israel
,
B. Brenner
1   Department of Hematology, Rambam Medical Center and Brace Rappaport Faculty of Medicine, Technion, Haifa, Israel
› Author Affiliations
Further Information

Publication History

Received 06 September 2001

Accepted 18 September 2001

Publication Date:
13 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Schulman S. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring and cost effectiveness. Semin Thromb Hemost 2000; 26: 421-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high dose factor VIIa in independent of tissue factor. Br J Hematol 1997; 99: 542-7.
    CrossrefPubMedGoogle Scholar
  • 3 Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Hemophilia 1999; 05: 253-9.
    CrossrefPubMedGoogle Scholar
  • 4 Kenet G, Walden R, Eldad A, Matinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. The Lancet 1999; 354: 1879.
    CrossrefPubMedGoogle Scholar
  • 5 Vlot AJ, Ton E, Mackaay AJ, Kramer MH, Gaillard CA. Treataent of a severely bleeding patient without pre-existing coagulopathy with activated recombinant factor VII. Am J Med 2000; 108: 421-2.
    CrossrefPubMedGoogle Scholar
  • 6 Hedner U. Recombinant factor VIIa (NOVOSEVEN®) as a hemostatic agent. In: 6th Novo Nordisk symposium on the treatment of bleeding and toombotic disorders. Copenhagen; Denmark: 2001
    Google Scholar
  • 7 Bernstein DE, Jeffers L, Erhordtsen E, Reddy KR, Glazer S, Squiban P, Bech R, Hedner U, Schiff ER. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-7.
    CrossrefPubMedGoogle Scholar
  • 8 Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, Van der Meer J. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: apilot study. Transplantation 2001; 71: 402-5.
    CrossrefPubMedGoogle Scholar
  • 9 Martinowitz U, Holcomb JB, Pusateri AE, Stein M, Onaca N, Freidman M, Macaitis JM, Castel D, Hedner U, Hess JR. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50: 721-9.
    CrossrefPubMedGoogle Scholar